Targeted Therapy in Pediatric and Adolescent Oncology
Targeted Therapy in Pediatric and Adolescent Oncology
复制标题
DOI：
10.1002/cncr.26050
复制
发表时间：
2011-05-15
期刊：
影响因子：
6.2
通讯作者：
Bernstein, Mark L.
中科院分区：
文献类型：
--
作者：
Bernstein, Mark L.
幸运的是，儿童和青少年的癌症并不常见。总的来说，治愈率很好，约为80%，尽管这因组织学和分期而异。靶向治疗旨在通过更特异性地影响恶性细胞或其支持基质来提高疗效并降低毒性。早期癌症的组织学通常与成人癌症不同。有时，即使组织学不同，也会影响相同的途径。毒性也可能不同，特别是在年幼的儿童中。这些因素使年轻人的药物开发具有挑战性。本文综述了这一发展的一些成功和挑战，包括伊马替尼，乐替尼，抗血管生成和抗GD 2治疗的简要讨论。Cancer 2011;117（10 suppl）：2268-74. (C)2011年美国癌症协会
Cancers in children and adolescents are fortunately infrequent. Overall, cure rates are good, approximately 80%, although this varies by histology and stage. Targeted therapies aim to improve efficacy and decrease toxicity by more specifically affecting malignant cells or their supporting stroma. Cancers of early life are often of different histology than those seen in adults. Sometimes, the same pathway is affected, even if the histology is different. Toxicities may also be different, particularly in younger children. These factors render drug development in young people challenging. This article reviews some successes and challenges to that development, including brief discussions of imatinib, lestaurtinib, antiangiogenesis, and anti-GD2 therapies. Cancer 2011;117(10 suppl):2268-74. (C) 2011 American Cancer Society